 |
MELBOURNE, Australia, May 27, 2024 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces it has submitted a New Drug Application (NDA) to the United States (U.S.) Food and Drug Administration (FDA) for TLX007-CDx, a new and proprietary cold kit ("Kit") for the preparation of PSMA-PET imaging[1] for prostate...
Read more: Telix Submits NDA for New Prostate Cancer Imaging Agent
Hashtag.net.au
In clinical settings, surgical supply partners aren’t just vendors. They sit quietly behind the scenes of operating lists, specialist consultations, treatment rooms and recovery workflows. When they...
Hashtag.net.au
The early developmental years of a child's life represent a critical window for neurological growth, behavioural shaping, and language acquisition. During this formative phase, the ability to interpre...
Hashtag.net.au
Finding the right family dentist in Sydney is one of the most important health decisions you can make for your household. With hundreds of practices spread across the city — from Beecroft to Bondi, Pa...